ID   STA-ET-2.1
AC   CVCL_9686
SY   STA-ET2.1; STA-ET-2_1; STAET2.1; St. Anna Kinderspital-Ewing Tumor-2.1
DR   EFO; EFO_0002863
DR   cancercelllines; CVCL_9686
DR   Cosmic; 1388902
DR   GEO; GSM510011
DR   IARC_TP53; 80
DR   IARC_TP53; 23643
DR   Progenetix; CVCL_9686
DR   Wikidata; Q54955771
RX   PubMed=8378080;
RX   PubMed=9393981;
RX   PubMed=15150091;
RX   PubMed=19787792;
RX   PubMed=21822310;
CC   From: Children's Cancer Research Institute; Vienna; Austria.
CC   Sequence variation: Gene deletion; HGNC; HGNC:1787; CDKN2A; Zygosity=Homozygous (PubMed=19787792).
CC   Sequence variation: Gene fusion; HGNC; HGNC:3508; EWSR1 + HGNC; HGNC:3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1 (PubMed=9393981).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Cys277Tyr (c.830G>A); ClinVar=VCV000185722; Zygosity=Unspecified (PubMed=8378080; PubMed=19787792).
CC   Omics: Array-based CGH.
CC   Omics: Transcriptome analysis by microarray.
ST   Source(s): PubMed=19787792
ST   Amelogenin: X,Y
ST   D16S539: 9,11
ST   D18S51: 15,17
ST   D19S433: 12,14
ST   D21S11: 30.2,31.2
ST   D2S1338: 16,19
ST   D3S1358: 17,18
ST   D5S818: 12
ST   D8S1179: 12,13
ST   FGA: 22,27
ST   SE33: 17,27.2
ST   TH01: 9
ST   TPOX: 12
ST   vWA: 15,17
DI   NCIt; C4817; Ewing sarcoma
DI   ORDO; Orphanet_319; Ewing sarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_9687 ! STA-ET-2.2
SX   Male
AG   15Y
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 19-12-24; Version: 21
//
RX   PubMed=8378080;
RA   Kovar H., Auinger A., Jug G., Aryee D.N.T., Zoubek A.,
RA   Salzer-Kuntschik M., Gadner H.;
RT   "Narrow spectrum of infrequent p53 mutations and absence of MDM2
RT   amplification in Ewing tumours.";
RL   Oncogene 8:2683-2690(1993).
//
RX   PubMed=9393981; DOI=10.1038/sj.onc.1201397;
RA   Kovar H., Jug G., Aryee D.N.T., Zoubek A., Ambros P.F., Gruber B.,
RA   Windhager R., Gadner H.;
RT   "Among genes involved in the RB dependent cell cycle regulatory
RT   cascade, the p16 tumor suppressor gene is frequently lost in the Ewing
RT   family of tumors.";
RL   Oncogene 15:2225-2232(1997).
//
RX   PubMed=15150091; DOI=10.1158/0008-5472.CAN-03-0809;
RA   Schaefer K.-L., Brachwitz K., Wai D.H., Braun Y., Diallo R.,
RA   Korsching E., Eisenacher M., Voss R., van Valen F., Baer C., Selle B.,
RA   Spahn L., Liao S.-K., Lee K.A.W., Hogendoorn P.C.W., Reifenberger G.,
RA   Gabbert H.E., Poremba C.;
RT   "Expression profiling of t(12;22) positive clear cell sarcoma of soft
RT   tissue cell lines reveals characteristic up-regulation of potential
RT   new marker genes including ERBB3.";
RL   Cancer Res. 64:3395-3405(2004).
//
RX   PubMed=19787792; DOI=10.1002/gcc.20717;
RA   Ottaviano L., Schaefer K.-L., Gajewski M., Huckenbeck W., Baldus S.E.,
RA   Rogel U., Mackintosh C., de Alava E., Myklebost O., Kresse S.H.,
RA   Meza-Zepeda L.A., Serra M., Cleton-Jansen A.-M., Hogendoorn P.C.W.,
RA   Buerger H., Aigner T., Gabbert H.E., Poremba C.;
RT   "Molecular characterization of commonly used cell lines for bone tumor
RT   research: a trans-European EuroBoNet effort.";
RL   Genes Chromosomes Cancer 49:40-51(2010).
//
RX   PubMed=21822310; DOI=10.1038/onc.2011.317;
RA   Mackintosh C., Ordonez J.L., Garcia-Dominguez D.J., Sevillano V.,
RA   Llombart-Bosch A., Szuhai K., Scotlandi K., Alberghini M., Sciot R.,
RA   Sinnaeve F., Hogendoorn P.C.W., Picci P., Knuutila S., Dirksen U.,
RA   Debiec-Rychter M., Schaefer K.-L., de Alava E.;
RT   "1q gain and CDT2 overexpression underlie an aggressive and highly
RT   proliferative form of Ewing sarcoma.";
RL   Oncogene 31:1287-1298(2012).
//